resisttb
- Nov 2, 2021
- 1 min read

Clinical trial results offer hope to DR-TB patients with short, effective treatment

TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB, who currently face lengthy treatment regimens. Read Here.

Recent Posts

See All

World TB Day 2023 Campaign Toolkit

The Stop TB Partnership today is releasing the campaign toolkit for this year’s World TB Day, 24 March 2023 Yes! We Can End TB. The theme brings attention toTB and our collective power to end TB by 20

Sutezolid with 3-drug combo appears safe and effective in multidrug-resistant TB

Adding the oxazolidinone antibiotic sutezolid to a three-drug combination appeared to be safe and effective for people with multidrug-resistant tuberculosis (TB), according to a dose-finding phase II

TAG's TB Treatment Pipeline Report Published

TAG has released its Pipeline Report regarding TB Treatment updates and results from trials completed in 2022 written by Lindsay McKenna. Read the report here!